Lu-177

Supply Chain

With rising demand and disrupted supply, IsoMedica’s high-purity Yb-176 production enhances reactor efficiency for Lu-177 cancer treatments. Backed by the South Australian Government, we are scaling up at the Advanced Radioisotope Production Facility (ARPF) to meet global needs.

Find Out More

Scientist working with Lu-177 isotopes for IsoMedica

Scientist reaching for sample in isolation tank

SECURING THE Lu-177 SUPPLY CHAIN

An established therapeutic isotope that emits beta-radiation, Lutetium-177 (Lu-177) efficiently kills nearby cancer cells when labelled to a cancer-seeking molecule. With over 100 clinical trials and the emergence of at least two billion dollar Lu-177 cancer treatments in recent years, the supply chain for Ytterbium-176 (Yb-176) is under immense pressure with traditional Russian sources no longer viable.

Advancing Radiopharmaceutical Production in South Australia

IsoMedica is able to produce Yb-176 at higher levels of purity than most market competitors, reducing issues with reactor operators to produce Lu-177 and thus, is in greater demand from end users. Our isotope purification process has much lower capital costs than competitors. With support from the South Australian Government through the Economic Recovery Grant, IsoMedica will scale up the existing lab scale project into the new Advanced Radioisotope Production Facility (ARPF) South Australia.

Isomedica Scientists working on nuclear medicines

OTher Projects

Medical Isotopes

212-Pb

Supply chain process for the manufacture of Lead-212 radiopharmaceuticals

Space & Defence

RHU

Generating heat for critical electronics and lithium batteries to survive the extreme low temperatures of the lunar night.

Space & Defence

GEN X

Maintenance-Free, long term Power for unmanned, remote and challenging Space and Defence applications.